Andere Sprachen ViaDerma, Inc.

Aktien

A113TU

US92555K1016

VDRM

Verzögert OTC Markets Andere Börsenplätze 21:43:00 15.07.2024			% 5 Tage	% 1. Jan.
0,00515 ^USD	+0,98 %		-10,34 %	-50,94 %

2023	ViaDerma, Inc. gibt Update des FDA-Zulassungsantrags und Markenname für neues Haarwuchsmittel bekannt	CI
2023	ViaDerma gibt die Absicht bekannt, ein neues Minoxidil-Haarwuchsmittel auf den Markt zu bringen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ViaDerma Provides Highlights of Quarterly Financial Report	06.06.
ViaDerma Update on Stability Testing, Global Sales Distribution, National Licensing, Nupelo & More	24.10.23
CapitalGainsReport: Top Stocks Under Two Cents To Radar Today (ATVK, VDRM, RNVA, ELTP)	22.08.23
BigTime Penny Stocks: Potential Break-Out Stocks to Watch (DPUI, RCIT, VDRM)	11.07.23
ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More	07.07.23
ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More	06.07.23
ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	16.03.23
ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	16.03.23
ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product	08.03.23
ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product	08.03.23
ViaDerma Provides an Update on Current & Future Business Activities	02.03.23
ViaDerma Retains Digital Marketing Leader INTENT SCIENCES to Accelerate Business Growth Online	12.01.23
ViaDerma Engages Intent Sciences to Power Up Digital Marketing & Brand Development	12.01.23
ViaDerma Successfully Completes Quality Control Testing of its New Vitastem Products	15.09.22
ViaDerma, Inc. Successfully Completes Quality Control Testing of Its New Vitastem Products	15.09.22
ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products	22.06.22
ViaDerma's 2021 Annual Report Shows Strong Revenue Growth Over the Previous Year	31.03.22
ViaDerma : Annual Report	30.03.22
ViaDerma : Attorney Letter with Respect to Current Information	21.12.21
ViaDerma : Set to Launch Two New and Improved Versions of its Flagship Product, Vitastem and Vitastem Ultra	04.10.21

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ViaDerma, Inc.

Aktien

A113TU

US92555K1016

VDRM

Andere Sprachen

Filter